Intra-Cellular TherapiesITCI
ITCI
About: Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. It maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Employees: 860
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
131% more call options, than puts
Call options by funds: $25.4M | Put options by funds: $11M
127% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 30
50% more funds holding in top 10
Funds holding in top 10: 10 [Q3] → 15 (+5) [Q4]
11% more capital invested
Capital invested by funds: $7.27B [Q3] → $8.08B (+$806M) [Q4]
8% more funds holding
Funds holding: 350 [Q3] → 379 (+29) [Q4]
1% less repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 134
2.68% less ownership
Funds ownership: 93.9% [Q3] → 91.22% (-2.68%) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$132
1%
upside
Avg. target
$132
1%
upside
High target
$132
1%
upside
4 analyst ratings
0 positive
0%
4 neutral
100%
0 negative
0%
Mizuho Graig Suvannavejh 38% 1-year accuracy 9 / 24 met price target | 1%upside $132 | Neutral Downgraded | 24 Feb 2025 |
Canaccord Genuity Sumant Kulkarni 25% 1-year accuracy 8 / 32 met price target | 1%upside $132 | Hold Downgraded | 31 Jan 2025 |
RBC Capital Brian Abrahams 15% 1-year accuracy 11 / 71 met price target | 1%upside $132 | Sector Perform Downgraded | 22 Jan 2025 |
Piper Sandler David Amsellem 60% 1-year accuracy 21 / 35 met price target | 1%upside $132 | Neutral Downgraded | 14 Jan 2025 |
Financial journalist opinion
Based on 5 articles about ITCI published over the past 30 days
Neutral
Business Wire
2 weeks ago
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellular Therapies, Inc. (NasdaqGS: ITCI) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Intra-Cellular will receive $132.00 in cash for each share of Intra-Cellular that they own. KSF is seeking to determine whether this consideration and the process t.
Neutral
Business Wire
2 weeks ago
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) to Johnson & Johnson for $132.00 per share in cash is fair to Intra-Cellular shareholders. Halper Sadeh encourages Intra-Cellular shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation.
Positive
Zacks Investment Research
2 weeks ago
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
Negative
Zacks Investment Research
3 weeks ago
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.30 per share a year ago.
Neutral
GlobeNewsWire
3 weeks ago
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results
Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million , representing a 51% increase over the same period in 2023
Positive
CNBC
1 month ago
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.
Negative
Benzinga
1 month ago
Top 4 Health Care Stocks You May Want To Dump In Q1
As of Jan. 21, 2025, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Neutral
PRNewsWire
1 month ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of Shareholders
NEW YORK , Jan. 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Enfusion, Inc. (NYSE: ENFN)'s sale to Clearwater Analytics for $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock. If you are an Enfusion shareholder, click here to learn more about your rights and options.
Neutral
Zacks Investment Research
2 months ago
Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer
JNJ is set to acquire ITCI for $132 per share in cash. The transaction is likely to close before this year's end.
Positive
Zacks Investment Research
2 months ago
Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last?
Intra-Cellular (ITCI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Charts implemented using Lightweight Charts™